Skip to main content
Close
Publication

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

See all publications

Results: A total of 326 patients were included. The baseline CD4+ cell count and plasma HIV-1 RNA were 387 (+/- 224) x 10(6) cells/l and 4 (+/- 1) log(10) respectively. The proportion of patients with plasma HIV-1 RNA 400 copies/ml at 24 weeks differed between genotyping and no genotyping arms (48.5 and 36.2%, P 0.05). Factors associated with a higher probability of plasma HIV-1 RNA 400 copies/ml were HIV-1 genotyping [odds ratio (OR), 1.7; 95% confidence interval (CI), 1.1-2.8; P = 0.016] and the expert advice in patients failing to a second-line antiretroviral therapy (OR, 3.2; 95% CI, 1.2-8.3; P = 0.016).

Conclusion: A total of 326 patients were included. The baseline CD4+ cell count and plasma HIV-1 RNA were 387 (+/- 224) x 10(6) cells/l and 4 (+/- 1) log(10) respectively. The proportion of patients with plasma HIV-1 RNA 400 copies/ml at 24 weeks differed between genotyping and no genotyping arms (48.5 and 36.2%, P 0.05). Factors associated with a higher probability of plasma HIV-1 RNA 400 copies/ml were HIV-1 genotyping [odds ratio (OR), 1.7; 95% confidence interval (CI), 1.1-2.8; P = 0.016] and the expert advice in patients failing to a second-line antiretroviral therapy (OR, 3.2; 95% CI, 1.2-8.3; P = 0.016).

Not available in
This is not available in . You can go to the translated versions in these languages: